NASDAQ:KALA - Kala Pharmaceuticals Stock Price, Forecast & News

Kala Pharmaceuticals trades on the NASDAQ under the ticker symbol "KALA."

Kala Pharmaceuticals Inc (NASDAQ:KALA) announced its quarterly earnings results on Wednesday, February, 12th. The company reported ($0.63) earnings per share for the quarter, missing the Thomson Reuters' consensus estimate of ($0.60) by $0.03. The company earned $1.18 million during the quarter, compared to analysts' expectations of $2.92 million. Kala Pharmaceuticals had a negative net margin of 1,553.29% and a negative return on equity of 173.83%. View Kala Pharmaceuticals' Earnings History.

Kala Pharmaceuticals is scheduled to release their next quarterly earnings announcement on Thursday, May 14th 2020. View Earnings Estimates for Kala Pharmaceuticals.

5 equities research analysts have issued 12 month price targets for Kala Pharmaceuticals' stock. Their forecasts range from $6.00 to $51.00. On average, they anticipate Kala Pharmaceuticals' share price to reach $18.20 in the next twelve months. This suggests a possible upside of 177.9% from the stock's current price. View Analyst Price Targets for Kala Pharmaceuticals.

5 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Kala Pharmaceuticals in the last year. There are currently 1 hold rating and 4 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for Kala Pharmaceuticals.

Media headlines about KALA stock have trended positive this week, according to InfoTrie. The research firm identifies negative and positive media coverage by analyzing more than six thousand news and blog sources in real time. The firm ranks coverage of companies on a scale of -5 to 5, with scores nearest to five being the most favorable. Kala Pharmaceuticals earned a media sentiment score of 2.6 on InfoTrie's scale. They also gave media stories about the company a news buzz of 0.0 out of 10, meaning that recent media coverage is extremely unlikely to have an impact on the stock's share price in the immediate future. View News Stories for Kala Pharmaceuticals.

Kala Pharmaceuticals saw a increase in short interest during the month of January. As of January 31st, there was short interest totalling 5,240,000 shares, an increase of 11.5% from the January 15th total of 4,700,000 shares. Based on an average daily volume of 545,600 shares, the days-to-cover ratio is currently 9.6 days. Approximately 19.4% of the shares of the stock are sold short. View Kala Pharmaceuticals' Current Options Chain.

Some companies that are related to Kala Pharmaceuticals include Achillion Pharmaceuticals (ACHN), I-Mab (ARQT), Radius Health (RDUS), Amphastar Pharmaceuticals (AMPH), Stoke Therapeutics (STOK), Cytokinetics (CYTK), Homology Medicines (FIXX), Phathom Pharmaceuticals (PHAT), Dova Pharmaceuticals (DOVA), Rhythm Pharmaceuticals (RYTM), ANI Pharmaceuticals (ANIP), Collegium Pharmaceutical (COLL), CannTrust (CNTTF), Frequency Therapeutics (FREQ) and DiaMedica Therapeutics (DMCAF).

Based on aggregate information from My MarketBeat watchlists, some companies that other Kala Pharmaceuticals investors own include Exelixis (EXEL), Amarin (AMRN), Nabriva Therapeutics (NBRV), SCYNEXIS (SCYX), Sorrento Therapeutics (SRNE), TG Therapeutics (TGTX), Zynerba Pharmaceuticals (ZYNE), Inovio Pharmaceuticals (INO), Viking Therapeutics (VKTX) and ACADIA Pharmaceuticals (ACAD).

(KALA) raised $90 million in an IPO on Thursday, July 20th 2017. The company issued 6,000,000 shares at a price of $14.00-$16.00 per share. J.P. Morgan and BofA Merrill Lynch served as the underwriters for the IPO and Wells Fargo Securities and Wedbush PacGrow were co-managers.

Kala Pharmaceuticals' stock is owned by a variety of of retail and institutional investors. Top institutional shareholders include Banco Bilbao Vizcaya Argentaria S.A. (4.06%), Sofinnova Investments Inc. (1.92%), Polaris Venture Management Co. V L.L.C. (1.64%), Alyeska Investment Group L.P. (1.27%), State Street Corp (1.05%) and Wedbush Securities Inc. (0.45%). Company insiders that own Kala Pharmaceuticals stock include Gregory Grunberg, Howard B Rosen and Ra Capital Healthcare Fund Lp. View Institutional Ownership Trends for Kala Pharmaceuticals.

KALA stock was sold by a variety of institutional investors in the last quarter, including Polaris Venture Management Co. V L.L.C., Goldman Sachs Group Inc., Bank of New York Mellon Corp, Bank of America Corp DE, Alambic Investment Management L.P. and Group One Trading L.P.. View Insider Buying and Selling for Kala Pharmaceuticals.

KALA stock was acquired by a variety of institutional investors in the last quarter, including Banco Bilbao Vizcaya Argentaria S.A., Sofinnova Investments Inc., Wedbush Securities Inc., State Street Corp, Alyeska Investment Group L.P., Virtu Financial LLC, UBS Group AG and Boston Partners. Company insiders that have bought Kala Pharmaceuticals stock in the last two years include Gregory Grunberg, Howard B Rosen and Ra Capital Healthcare Fund Lp. View Insider Buying and Selling for Kala Pharmaceuticals.

Shares of KALA can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity and Charles Schwab.

One share of KALA stock can currently be purchased for approximately $6.55.

Kala Pharmaceuticals has a market capitalization of $241.07 million and generates $6.07 million in revenue each year. The company earns $-94,350,000.00 in net income (profit) each year or ($2.76) on an earnings per share basis. Kala Pharmaceuticals employs 130 workers across the globe.View Additional Information About Kala Pharmaceuticals.

The official website for Kala Pharmaceuticals is http://www.kalarx.com/.

Kala Pharmaceuticals' mailing address is 490 ARSENAL WAY SUITE 120, WATERTOWN MA, 02472. The company can be reached via phone at 781-996-5252 or via email at [email protected]